secwatch.observer — SEC 8-K summary
======================================

Issuer:     IONIS PHARMACEUTICALS INC (IONS)
CIK:        0000874015
Form:       8-K
Filed at:   2023-02-22T23:59:59+00:00
Accession:  0001140361-23-007944
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ionis reports FY2022 revenue $587M, net loss $270M; eplontersen NDA submitted; 2023 guidance revenue >$575M
--------------------------------------------------------------------------------

- FY2022 total revenue $587M (down from $810M in 2021); net loss $270M vs $29M loss in 2021.
- Q4 2022 revenue $152M, net loss $52M; non-GAAP net loss $168M.
- Eplontersen NDA submitted to FDA for ATTRv-PN; tofersen under FDA/EMA review; olezarsen Fast Track for FCS.
- 2023 guidance: revenue >$575M, non-GAAP operating expenses ~$970-995M, net operating loss <$425M.
- Cash, cash equivalents and short-term investments $2.0B at Dec 31, 2022; plus $500M from Royalty Pharma in Jan 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874015/000114036123007944/0001140361-23-007944-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874015/000114036123007944/brhc10048570_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-007944

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer